Feb. 7 at 7:18 AM
$CERO CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient | Markets Insider https://share.google/Qw5ViBxYd4O4qiDyS